At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Zn-DDC (drug), Lanalidomide with Zn-DDC (drug), Pomalidomide with Zn-DDC (drug)
- How long the study runs
- Study runs about 74 months (dates as stated)
- About the drug or intervention
- Zn-DDC — drug: Zn-DDC added to myeloma samples for culturing · Lanalidomide with Zn-DDC — drug: Lanalidomide with Zn-DDC added to myeloma samples for culturing · Pomalidomide with Zn-DDC — drug: Lanalidomide with Zn-DDC added to myeloma samples for culturing
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 70
- Started
- 2021-10-22
- Last checked
- 2026-04
Plain English Summary
What is this study?
- • Testing a new treatment for multiple myeloma
- • Clinical study - 70 participants
- • The outlook for patients with haematological malignancies remains challenging
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with multiple myeloma
Where?
- • Wolverhampton - The Royal Wolverhampton NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma and other haematological malignancies. This may lead to potential combination therapies which will be very effective as well as affordable in the future. There is the need to look to see if this drug, Imuthiol and along with complementary drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological malignancy treatment. In order to do this there is the need to see how the cancer cells respond to the drugs in the laboratory before being able to trial the drug (or combination of drugs) out for treatment. The success of this study may lead to quick translation of Imuthiol into haematological malignancy treatment.
More detail
Up to 60 myeloma bone marrow samples from Myeloma patients and 10 bone marrow samples from other haematological malignancy samples (Acute leukaemia's) at Diagnosis and Relapse will be tested. Patients attending haematology clinics at New Cross Hospital will be reviewed for eligibility of the study by the clinician and if they meet the recruitment criteria, they will be approached to participate at clinic. After informed consent, participants will be asked to donate an additional 2-3ml sample of bone marrow in a single aliquot for the purpose of this study whilst undergoing a bone marrow aspirate as part of their routine clinical care at diagnosis and relapse.The single aliquot will be sent to the University of Wolverhampton for analysis. Specific clincial data will be collected at the time of diagnosis and relapse: * Diagnosis * Date diagnosed * Disease stage * Relapse status * Age * Sex * Previous treatments * Date of marrow sample * Marrow trephine * Marrow liquid The clinical data set will remain at The Royal Wolverhampton NHS Trust whilst analysis of the samples takes place. Once the samples have been analysed, the clinical data will then be released to determine relapsed or refractory disease and correlation with the in vitro data.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Patients diagnosed with haematological cancer - either myeloma or acute leukaemia
- ✓Patients must be 18 years or over
- ✓Patients must be willing and able to give agreement to take part
Who cannot take part
- ✗Pregnant patients will not be entered
See the full criteria
Where Is This Study? (1 UK site)
The Royal Wolverhampton NHS Trust
Wolverhampton WV10 0QP, United Kingdom
How to Get in Touch
Supratik Basu
Sponsor contactCONTACT
Lorraine Jacques
Sponsor contactCONTACT